Photo: Courtesy of Teva

27 July 2015Asia

Teva buys Allergan Generics in $40bn deal

Pharmaceutical company Teva has bought Allergan Genericsfrom drugs business Allerganin a $40.5 billion deal.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Teva fails to reclassify MS drug to thwart generics

5 January 2021 Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.

Allergan sees off glaucoma patent challenges

5 August 2015 Drugs companies Sandoz and Lupin have failed to reverse a US court’s ruling that they infringed patents owned by Allergan.

More on this story

Teva fails to reclassify MS drug to thwart generics

5 January 2021 Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.

Allergan sees off glaucoma patent challenges

5 August 2015 Drugs companies Sandoz and Lupin have failed to reverse a US court’s ruling that they infringed patents owned by Allergan.

More on this story

Teva fails to reclassify MS drug to thwart generics

5 January 2021 Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.

Allergan sees off glaucoma patent challenges

5 August 2015 Drugs companies Sandoz and Lupin have failed to reverse a US court’s ruling that they infringed patents owned by Allergan.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB